Bristol-Myers Squib
NICE reverses stance on Celgene’s Revlimid for myeloma maintenance
Phil Taylor
Bristol-Myers Squib, Cancer Drugs Fund, Celgene, Haematology, multiple myeloma, NHS, NICE, Oncology, Revlimid, UK
0 Comment
R&D/ Views & Analysis/ Views and analysis
The future of real world evidence
mike.hammerton@pharmaphorum.com
BMS, Bristol-Myers Squib, Pfizer, real world data, Real World Evidence, RWD, RWE
0 Comment
FDA approves Bayer/Janssen’s Xarelto in new blood clot prevention use
Richard Staines
Bayer, Boehringer Ingelheim, Bristol-Myers Squib, Janssen
0 Comment
Keytruda wins another first with approval based on biomarkers
Richard Staines
biomarker, Bristol-Myers Squib, cancer, fda, immuno-oncology, Merck & Co
0 Comment
For the first time, FDA approves drug on the basis of biomarkers, rather than location.